Gene therapy: Have the risks associated with viral vectors been solved?

Current Opinion in Molecular Therapeutics

Volumn 12, Issue 6, 2010, Pages 637-638

  Auman, J Todd ^a  

^a University of North Carolina   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LENTIVIRUS VECTOR; VIRUS VECTOR;

BETA THALASSEMIA; CYSTIC FIBROSIS; GENE THERAPY; HUMAN; IMMUNE RESPONSE; MONOGENIC DISORDER; MUSCULAR DYSTROPHY; ONCOGENE; ORNITHINE TRANSCARBAMYLASE DEFICIENCY; PROTEIN EXPRESSION; RETROVIRUS; REVIEW; SICKLE CELL ANEMIA; X LINKED SEVERE COMBINED IMMUNODEFICIENCY;

GENE THERAPY; GENETIC VECTORS; HUMANS; RISK ASSESSMENT; RISK FACTORS; VIRUSES;

EID: 79952912106     PISSN: 14648431     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (11)

1. Friedmann T, Roblin R: Gene therapy for human genetic disease? Science (1972) 175(25):949-955.
2. Marshall E: Gene therapy death prompts review of adenovirus vector. Science (1999) 286(5448):2244-2245. (Pubitemid 30016842) (Pubitemid 30016842)
3. Hacein-Bey-Abina S, von Kalle C, Schmidt M, Le Deist F, Wulffraat N, McIntyre E, Radford I, Villeval J-L, Fraser CC, Cavazzana-Calvo M, Fischer A: A serious adverse event after successful gene therapy for X-linked severe combined immunodefciency. N Engl J Med (2003) 348(3):255-256. (Pubitemid 36077924) (Pubitemid 36077924)
4. Cattoglio C, Facchini G, Sartori D, Antonelli A, Miccio A, Cassani B, Schmidt M, von Kalle C, Howe S, Thrasher AJ, Aiuti A et al: Hot spots of retroviral integration in human CD34+ hematopoietic cells. Blood (2007) 110(6):1770-1778. (Pubitemid 47443887) (Pubitemid 47443887)
5. Cavazzana-Calvo M, Payen E, Negre O, Wang G, Hehir K, Fusil F, Down J, Denaro M, Brady T, Westerman K, Cavallesco R et al: Transfusion independence and HMGA2 activation after gene therapy of human β-thalassaemia. Nature 467(7313) 318-322.
6. Fedele M, Fusco A: HMGA and cancer. Biochim Biophys Acta (2010) 1799(1-2):48-54.
7. Mendell JR, Campbell K, Rodino-Klapac L, Sahenk Z, Shilling C, Lewis S, Bowles D, Gray S, Li C, Galloway G, Malik V et al: Dystrophin immunity in Duchenne's muscular dystrophy. N Engl J Med 363(15):1429-1437.
8. Alexander B, Warner-Schmidt J, Eriksson T, Tamminga C, Arango-Llievano M, Ghose S, Vernov M, Stavarche M, Musatov S, Flajolet M, Svenningsson P et al: Reversal of depressed behaviors in mice by p11 gene therapy in the nucleus accumbens. Sci Transl Med 2:54ra76.
9. Bartosch B, Cosset FL: Strategies for retargeted gene delivery using vectors derived from lentiviruses. Curr Gene Ther (2004) 4(4):427-443. (Pubitemid 39534757) (Pubitemid 39534757)
10. Yi Y, Hahm SH, Lee KH: Retroviral gene therapy: Safety issues and possible solutions. Curr Gene Ther (2005) 5(1):25-35. (Pubitemid 40246740) (Pubitemid 40246740)
11. Jooss K, Chirmule N: Immunity to adenovirus and adeno-associated viral vectors: Implications for gene therapy. Gene Ther (2003) 10(11):955-963. (Pubitemid 36722430) (Pubitemid 36722430)